LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Transcript
LifeVantage Corporation ( LFVN ) Q1 2026 Earnings Call November 4, 2025 4:30 PM EST Company Participants Steven Fife - President, CEO & Director Carl Aure - Chief Financial Officer Conference Call Participants Reed Anderson - ICR Inc. Douglas Lane - Water Tower Research LLC Presentation Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
LifeVantage Corporation (LFVN) Q4 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q4 2025 Earnings Call September 4, 2025 4:30 PM EDT Company Participants Steven Fife - President, CEO & Director Carl Aure - Chief Financial Officer Conference Call Participants Reed Anderson - ICR Inc. Douglas Lane - Water Tower Research LLC Presentation Operator Good day, ladies and gentlemen. Thank you for standing by.
The LifeVantage Advantage: High Retention, High Returns
LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN's growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream.
LifeVantage Corporation (LFVN) Q3 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q3 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Reed Anderson - Managing Director-ICR Steve Fife - President and Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.
LifeVantage: Activation Of Shareholder Value
LifeVantage (LFVN) is a mispriced opportunity with potential for >15% IRR, driven by its new GLP-1 product suite and turnaround signals. LFVN's valuation is attractive at ~6x EV/EBITDA and a Fwd PEG of 0.15x, trading below sector median despite strong growth potential. The company's revamped business model and compensation package have increased active accounts by 25%, indicating early signs of success turnaround and enhanced sales outreach which the market is not reacting.
LifeVantage: Post-Earnings Selloff Provides Buying Opportunity
LifeVantage Corporation's Q2/FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%.
LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure – Chief Financial Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Alex Fuhrman – Craig-Hallum Capital Group Doug Lane – Water Tower Research Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's Second Quarter of Fiscal 2025 Results.
Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering investment ideas and encouraging discussion among investors. Pacifica Yield highlights Brookfield Infrastructure's subordinated notes with a 32% discount opportunity and a 7.2% yield, backed by a strong balance sheet and diversified assets. Cerence Inc.'s partnership with Nvidia boosts its AI capabilities according to Uttam Dey, but caution is advised due to recent stock surge and potential volatility.
LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs from the likes of Zepbound and Ozempic. The recent launch has exceeded expectations by a wide margin. On Wednesday, the company preannounced stellar Q2/FY2025 results. Preliminary Q2/FY2025 revenues of $67.5 million exceeded consensus expectations by more than 30% and active accounts of approximately 146,000 represented the highest level in almost two years.
Top 3 Risk Off Stocks That May Collapse This Month
As of Dec. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
LifeVantage Corporation (LFVN) Q1 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q1 2025 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - President & Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Douglas Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.
LifeVantage Corporation (LFVN) Q4 2024 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q4 2024 Earnings Conference Call August 28, 2024 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - President & CEO Carl Aure - CFO Conference Call Participants Douglas Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.
